Qiagen N.V. with U.S. divisions in Germantown and Gaithersburg has extended an offer to purchase France based Ipsogen S.A.
The exclusive negotiations include a 47% preliminary stake, afterwards, Qiagen plans to purchase the remaining shares in Ipsogen.
Ipsogen is a cancer profiler, the company develops tests that guide patients and doctors through mapping diseases. The purchase fits in with Qiagen which also develops tests in the form of sample and assay technologies which help biomedical researchers and companies process and isolate DNA, RNA and proteins.
Ipsogen revenue grew 24% in 2010, it has its U.S. operations in Stamford, CT.
Netherlands based Qiagen has an approximate market cap of $4.37 billion and over 3,500 employees worldwide.